

# Renato Zambello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6606376/publications.pdf>

Version: 2024-02-01

293  
papers

10,158  
citations

38742

50  
h-index

48315

88  
g-index

293  
all docs

293  
docs citations

293  
times ranked

9237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel STAT5B mutations and characterization of TCR $\beta^2$ signatures in CD4+ T-cell large granular lymphocyte leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 31.	6.2	15
2	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. <i>Nature Communications</i> , 2022, 13, 1981.	12.8	23
3	Interrogating molecular genetics to refine LGLL classification. <i>Blood</i> , 2022, 139, 3002-3004.	1.4	6
4	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. <i>Leukemia</i> , 2022, 36, 1947-1950.	7.2	9
5	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	1.6	29
6	Defining TCR $\beta^+$ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. <i>Nature Communications</i> , 2022, 13, .	12.8	7
7	Large Granular Lymphocyte Leukemia. <i>Hematologic Malignancies</i> , 2021, , 231-246.	0.2	0
8	The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients. <i>Dentistry Journal</i> , 2021, 9, 11.	2.3	3
9	MATRIX $\text{\textcircled{R}}$ RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	4.6	54
10	Chimerism Monitoring Techniques after Hematopoietic Stem Cell Transplantation: An Overview of the Last 15 Years of Innovations. <i>Diagnostics</i> , 2021, 11, 621.	2.6	16
11	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. <i>PLoS ONE</i> , 2021, 16, e0247717.	2.5	10
12	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. <i>Cancer</i> , 2021, 127, 2015-2024.	4.1	2
13	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age $\geq 80$ in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	6.2	7
14	Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8002-8002.	1.6	22
15	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 682658.	2.8	2
16	Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf. <i>Pharmaceuticals</i> , 2021, 14, 40.	3.8	8
17	Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options. <i>Cells</i> , 2021, 10, 2800.	4.1	16
18	Protein Kinase CK1 $\beta$ Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 733848.	2.8	4

#	ARTICLE	IF	CITATIONS
19	Synergistic Role of Leukemic and Non-Leukemic Immune Repertoires in CD8+ T-Cell Large Granular Lymphocytic Leukemia As Identified By Single-Cell Transcriptomics. <i>Blood</i> , 2021, 138, 1318-1318.	1.4	1
20	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	10.7	120
21	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	6.2	5
22	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16
23	Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. <i>Leukemia</i> , 2020, 34, 1116-1124.	7.2	49
24	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. <i>British Journal of Haematology</i> , 2020, 188, 907-917.	2.5	8
25	Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. <i>Chest</i> , 2020, 158, 2602-2609.	0.8	5
26	<p>Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7605-7614.	2.0	2
27	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020, 10, 58.	6.2	9
28	Identification of a <i>miR-146b</i>-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. <i>Haematologica</i> , 2020, 105, 1351-1360.	3.5	28
29	Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research. <i>Frontiers in Oncology</i> , 2020, 10, 802.	2.8	3
30	Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 152.	2.8	40
31	Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 312-315.	3.1	11
32	Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. <i>Blood Cancer Journal</i> , 2020, 10, 18.	6.2	14
33	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17
34	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	1.7	7
35	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the. 2020, 7, e456-e468.	4.6	244
36	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. <i>Cells</i> , 2020, 9, 768.	4.1	27

#	ARTICLE	IF	CITATIONS
37	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. <i>Blood Cancer Journal</i> , 2020, 10, 42.	6.2	22
38	Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?. <i>Frontiers in Oncology</i> , 2020, 10, 613570.	2.8	3
39	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. <i>Blood</i> , 2020, 136, 35-37.	1.4	37
40	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
41	Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial. <i>Blood</i> , 2020, 136, 27-28.	1.4	0
42	Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. <i>Blood</i> , 2020, 136, 27-28.	1.4	3
43	Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel. <i>Blood</i> , 2020, 136, 38-39.	1.4	4
44	Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
45	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. <i>Cell Death Discovery</i> , 2019, 5, 98.	4.7	22
46	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 2096-2107.	13.7	435
47	T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 207-216.	1.7	37
48	Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study. <i>British Journal of Haematology</i> , 2019, 186, e13-e17.	2.5	3
49	Immune Profiling of Plasma Cell Dyscrasias Reveals a Therapy Related T-Cell Modulation in Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e87.	0.4	0
50	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e271.	0.4	0
51	Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI. <i>Annals of Hematology</i> , 2019, 98, 679-689.	1.8	13
52	Phase III trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. <i>British Journal of Haematology</i> , 2019, 185, 944-947.	2.5	5
53	Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 4322-4322.	1.4	15
54	MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. <i>Blood</i> , 2019, 134, 4321-4321.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial. <i>Blood</i> , 2019, 134, 353-353.	1.4	2
56	Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study. <i>Blood</i> , 2019, 134, 3195-3195.	1.4	0
57	Overexpression and Targeted Activation of the Protein Phosphatases SHP-1 Abrogates Survival Pathways in Large Granular Lymphocyte Leukemia (LGLL). <i>Blood</i> , 2019, 134, 2798-2798.	1.4	0
58	Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability. <i>Blood</i> , 2019, 134, 5555-5555.	1.4	0
59	Whole Exome Sequencing Analysis in Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) Patients Fails to Detect Significant Viral Load. <i>Blood</i> , 2019, 134, 5214-5214.	1.4	0
60	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian “Back to Life”™ project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	3.1	9
61	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 20.	6.2	19
62	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. <i>Blood Cancer Journal</i> , 2018, 8, 51.	6.2	20
63	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.4	9
64	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. <i>Blood</i> , 2018, 132, 125-125.	1.4	10
65	Pustular eruption associated with granulocyte colony-stimulating factor treatment. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 276-277.	0.2	0
66	Insights into the Molecular Mechanism Accounting for Neutropenia in T-Large Granular Lymphocytes Leukemia. <i>Blood</i> , 2018, 132, 1575-1575.	1.4	0
67	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. <i>Blood</i> , 2018, 132, 2023-2023.	1.4	0
68	Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years. <i>Blood</i> , 2018, 132, 1688-1688.	1.4	0
69	Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2017, 96, 159-161.	1.8	15
70	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	4.6	28
71	IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1094-1097.	1.9	28
72	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	4.6	106

#	ARTICLE	IF	CITATIONS
73	Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. <i>Clinical Radiology</i> , 2017, 72, 850-857.	1.1	38
74	Infections in Multiple Myeloma: An Underestimate Risk Factor of Comorbidity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e30.	0.4	0
75	Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e7.	0.4	5
76	Hyperammonemic Encephalopathy as Initial Presentation of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e102-e103.	0.4	0
77	Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e118.	0.4	0
78	Protein kinase CK2 regulates AKT, NF- $\kappa$ B and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 292-300.	7.2	55
79	Steroid-responsive hyperammonemic encephalopathy as first manifestation of multiple myeloma. <i>Neurological Sciences</i> , 2017, 38, 503-505.	1.9	2
80	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017, 35, 925-928.	1.7	19
81	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8003-8003.	1.6	13
82	Inactivation of CK1 $\alpha$ in multiple myeloma empowers drug cytotoxicity by affecting AKT and $\beta$ -catenin survival signaling pathways. <i>Oncotarget</i> , 2017, 8, 14604-14619.	1.8	30
83	<i>STAT3</i> mutation impacts biological and clinical features of T-LGL leukemia. <i>Oncotarget</i> , 2017, 8, 61876-61889.	1.8	67
84	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	1.8	25
85	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
86	Lenalidomide long-term neurotoxicity. <i>Neurology</i> , 2016, 87, 1161-1166.	1.1	31
87	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	1.3	30
88	Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University. <i>Blood</i> , 2016, 128, 2527-2527.	1.4	6
89	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016, 128, 472-472.	1.4	2
90	A Pyrazolo[3,4- <i>d</i> ]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. <i>Oncotarget</i> , 2016, 7, 65171-65184.	1.8	18



#	ARTICLE	IF	CITATIONS
91	The Atypical Gtpase Rhou Lies Downstream IL6/STAT3 and Regulates Myeloma Plasma Cells Adhesion/Motility. <i>Blood</i> , 2016, 128, 5661-5661.	1.4	0
92	Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial. <i>Blood</i> , 2016, 128, 474-474.	1.4	1
93	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. <i>Haematologica</i> , 2015, 100, e515-e518.	3.5	48
94	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. <i>Oncotarget</i> , 2015, 6, 42130-42149.	1.8	39
95	Bendamustine in relapsed/refractory multiple myeloma: the "œreal-life" side of the moon. <i>Leukemia and Lymphoma</i> , 2015, 56, 1510-1513.	1.3	7
96	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 612-620.e5.	0.4	26
97	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. <i>American Journal of Hematology</i> , 2015, 90, 515-523.	4.1	51
98	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 48-52.	2.2	29
99	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 592-598.	0.4	2
100	High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3903-3910.	1.6	99
101	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1571-1580.	2.2	36
102	Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience. <i>Blood</i> , 2015, 126, 2710-2710.	1.4	3
103	A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells. <i>Blood</i> , 2015, 126, 3254-3254.	1.4	1
104	Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells. <i>Blood</i> , 2015, 126, 3876-3876.	1.4	1
105	Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial. <i>Blood</i> , 2015, 126, 1547-1547.	1.4	1
106	Cyclophosphamide as a first-line therapy in LGL leukemia. <i>Leukemia</i> , 2014, 28, 1134-1136.	7.2	74
107	Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?. <i>Frontiers in Immunology</i> , 2014, 5, 72.	4.8	22
108	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and $\gamma$ inhibition by nocodazole. <i>British Journal of Haematology</i> , 2014, 165, 659-672.	2.5	26

#	ARTICLE	IF	CITATIONS
109	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. <i>Leukemia</i> , 2014, 28, 2094-2097.	7.2	14
110	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective caseâ€matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.	4.1	24
111	Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. <i>Annals of Oncology</i> , 2014, 25, 2030-2035.	1.2	49
112	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198
113	Psoriasis induced by thalidomide in a patient with multiple myeloma. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204469-bcr2014204469.	0.5	3
114	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. <i>Haematologica</i> , 2014, 99, 1826-1833.	3.5	21
115	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 1069-1077.	3.5	32
116	High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial. <i>Blood</i> , 2014, 124, 1724-1724.	1.4	1
117	Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients. <i>Blood</i> , 2014, 124, 197-197.	1.4	5
118	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	1.4	5
119	Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors. <i>Blood</i> , 2014, 124, 5508-5508.	1.4	4
120	Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts) with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A multicenter phase II trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 8577-8577.	1.6	0
121	Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3321-3321.	1.4	0
122	Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?. <i>Translational Medicine @ UniSa</i> , 2014, 8, 4-11.	0.5	14
123	Bendamustine salvage therapy for T cell neoplasms. <i>Annals of Hematology</i> , 2013, 92, 1249-1254.	1.8	30
124	NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2013, 331, 86-89.	0.6	4
125	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. <i>Journal of Hematology and Oncology</i> , 2013, 6, 78.	17.0	46
126	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higherâ€risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	2.2	37



#	ARTICLE	IF	CITATIONS
127	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1442-1449.	1.6	167
128	Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 19-24.	3.1	18
129	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. <i>Blood</i> , 2013, 121, 3843-3854.	1.4	85
130	Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study. <i>Blood</i> , 2013, 122, 2090-2090.	1.4	6
131	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethasone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	1.4	13
132	Protein Kinase CK2 Inhibition Down Modulates the NF- $\kappa$ B and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. <i>PLoS ONE</i> , 2013, 8, e75280.	2.5	75
133	T Large Granular Lymphocytes Leukemia (T-LGLL) and Natural Killer Chronic Lymphoproliferative Disorder (NK-CLPD): Two Diseases With a Common Etiopathogenetic Mechanism?. <i>Blood</i> , 2013, 122, 2612-2612.	1.4	0
134	LGL Disorders: From An Inflammatory-Mediated To a Self-Maintaining Proliferation. <i>Blood</i> , 2013, 122, 4889-4889.	1.4	0
135	Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 33-37.	1.9	24
136	The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. <i>Laboratory Investigation</i> , 2012, 92, 1574-1582.	3.7	71
137	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. <i>Clinical Cancer Research</i> , 2012, 18, 1888-1900.	7.0	71
138	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2012, 120, 9-19.	1.4	305
139	HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen. <i>PLoS ONE</i> , 2012, 7, e39902.	2.5	29
140	State of the art in natural killer cell malignancies. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 117-128.	1.3	23
141	Pachymeningeal involvement in POEMS syndrome: Dramatic cerebral MRI improvement after lenalidomide therapy. <i>American Journal of Hematology</i> , 2012, 87, 539-541.	4.1	12
142	Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2012, 120, 4068-4068.	1.4	3
143	Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4210-4210.	1.4	1
144	Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.. <i>Blood</i> , 2012, 120, 2971-2971.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 4860-4860.	1.4	0
146	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	1.6	302
147	Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2011, 25, 1768-1781.	7.2	55
148	Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. <i>Clinical Neurophysiology</i> , 2011, 122, 2518-2522.	1.5	13
149	KIR/HLA mismatching and risk of relapse in paediatric patients undergoing nonhaploidentical allogeneic haematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2011, 15, 198-204.	1.0	11
150	Aggressive LGL leukaemia presentation in old age. <i>Annals of Hematology</i> , 2011, 90, 603-606.	1.8	0
151	Primary Cutaneous Mantle Cell Lymphoma. <i>Acta Dermato-Venereologica</i> , 2011, 91, 474-475.	1.3	16
152	Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 1871-1871.	1.4	4
153	Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant. <i>Blood</i> , 2011, 118, 2677-2677.	1.4	5
154	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 1867-1867.	1.4	0
155	Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia. <i>Blood</i> , 2011, 118, 1375-1375.	1.4	0
156	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. <i>Haematologica</i> , 2010, 95, 1722-1729.	3.5	24
157	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. <i>BMC Cancer</i> , 2010, 10, 526.	2.6	39
158	Lenalidomide for bortezomib-resistant multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	27.6	6
159	NKG2A inhibits NKG2C effector functions of $\gamma\delta$ T cells: implications in health and disease. <i>Journal of Leukocyte Biology</i> , 2010, 89, 75-84.	3.3	38
160	Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors. <i>Blood</i> , 2010, 116, 620-620.	1.4	10
161	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients. <i>Blood</i> , 2010, 116, 1939-1939.	1.4	0
162	Cortactin Is Overexpressed In Neoplastic Cells of Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 2436-2436.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. <i>Haematologica</i> , 2009, 94, 1341-1345.	3.5	36
164	Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and Nkp30. <i>Experimental Hematology</i> , 2009, 37, 1167-1175.	0.4	15
165	Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy. <i>Journal of the Peripheral Nervous System</i> , 2009, 14, 146-148.	3.1	8
166	Clinical spectrum of $\gamma\delta$ + T cell LGL leukemia: Analysis of 20 cases. <i>Leukemia Research</i> , 2008, 32, 45-48.	0.8	65
167	Phenotypical and functional evaluation of CD8+/S6F1+ T lymphocytes in haemophilic individuals with HIV-1 infection. <i>Clinical and Experimental Immunology</i> , 2008, 93, 51-55.	2.6	5
168	LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY. <i>Neurology</i> , 2008, 71, 1742-1744.	1.1	75
169	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. <i>Blood</i> , 2008, 112, 4665-4674.	1.4	53
170	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
171	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008, 112, 3017-3017.	1.4	17
172	Effects of CK2 Inhibition on Multiple Signaling Pathways in Myeloma Cells. <i>Blood</i> , 2008, 112, 5163-5163.	1.4	0
173	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. <i>Journal of Leukocyte Biology</i> , 2007, 82, 946-955.	3.3	43
174	Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 823-829.	0.8	48
175	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. <i>Leukemia Research</i> , 2007, 31, 371-377.	0.8	14
176	Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. <i>Leukemia</i> , 2007, 21, 1060-1069.	7.2	40
177	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. <i>British Journal of Haematology</i> , 2007, 138, 594-602.	2.5	44
178	Role of Protein Kinase CK2 in the Retinoic Acid-Induced Differentiation of Acute Promyelocytic Leukemia Cells. <i>Blood</i> , 2007, 110, 879-879.	1.4	1
179	Multiple myeloma cell survival relies on high activity of protein kinase CK2. <i>Blood</i> , 2006, 108, 1698-1707.	1.4	123
180	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006, 30, 283-285.	0.8	17

#	ARTICLE	IF	CITATIONS
181	Role of Hematopoietic-Specific Protein 1 (HS1) in Apoptosis in B-Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2809-2809.	1.4	0
182	Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
183	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood, 2005, 106, 3926-3931.	1.4	30
184	Role for CXCR6 and Its Ligand CXCL16 in the Pathogenesis of T-Cell Alveolitis in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1290-1298.	5.6	81
185	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respiratory Research, 2005, 6, 20.	3.6	26
186	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	192
187	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	117
188	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. Journal of Leukocyte Biology, 2004, 75, 798-804.	3.3	15
189	Rituximab-responsive CIDP. European Journal of Neurology, 2004, 11, 788-788.	3.3	53
190	The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes. Leukemia, 2004, 18, 771-776.	7.2	3
191	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood, 2004, 104, 502-508.	1.4	144
192	Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2.. Blood, 2004, 104, 643-643.	1.4	2
193	Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).. Blood, 2004, 104, 903-903.	1.4	0
194	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 2003, 120, 765-773.	2.5	9
195	Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Seminars in Hematology, 2003, 40, 201-212.	3.4	35
196	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	1.4	106
197	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2002, 100, 1559-1565.	1.4	89
198	Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atherosclerosis, 2001, 158, 73-79.	0.8	54

#	ARTICLE	IF	CITATIONS
199	Identification of NKp80, a novel triggering molecule expressed by human NK cells. <i>European Journal of Immunology</i> , 2001, 31, 233-242.	2.9	185
200	Detection of <i>Chlamydomydia pneumoniae</i> DNA in peripheral blood mononuclear cells of blood donors in the north-east of Italy. <i>Medical Microbiology and Immunology</i> , 2001, 190, 139-144.	4.8	16
201	Antiapoptotic Effects of IL-15 on Pulmonary Tc1 Cells of Patients with Human Immunodeficiency Virus Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 484-489.	5.6	15
202	B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. <i>Cancer</i> , 2000, 89, 1259-1268.	4.1	23
203	Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. <i>British Journal of Haematology</i> , 2000, 108, 717-723.	2.5	36
204	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 2000, 96, 647-654.	1.4	19
205	CXC Chemokines IP-10 and Mig Expression and Direct Migration of Pulmonary CD8 + /CXCR3 + T Cells in the Lungs of Patients with HIV Infection and T-Cell Alveolitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1466-1473.	5.6	95
206	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 2000, 96, 647-654.	1.4	7
207	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L240-L250.	2.9	35
208	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€™T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286.	1.4	25
209	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1999, 106, 119-127.	2.5	6
210	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. <i>Journal of Clinical Investigation</i> , 1999, 104, 115-121.	8.2	134
211	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€™T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286.	1.4	11
212	The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. <i>Clinical and Experimental Immunology</i> , 1998, 111, 564-573.	2.6	10
213	Impaired cytokine production by neutrophils isolated from patients with AIDS. <i>Aids</i> , 1998, 12, 373-379.	2.2	25
214	Selection of T lymphocytes bearing limited TCR-Vbeta regions in the lung of hypersensitivity pneumonitis and sarcoidosis.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 155, 587-596.	5.6	34
215	Interleukin-15: A Novel Cytokine with Regulatory Properties on Normal and Neoplastic B Lymphocytes. <i>Leukemia and Lymphoma</i> , 1997, 27, 35-42.	1.3	39
216	The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis. <i>Blood</i> , 1997, 89, 256-260.	1.4	324

#	ARTICLE	IF	CITATIONS
217	Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes. <i>Blood</i> , 1997, 89, 201-211.	1.4	106
218	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. <i>Blood</i> , 1997, 90, 1115-1123.	1.4	51
219	Seroreactivity to an Envelope Protein of Human T-Cell Leukemia/Lymphoma Virus in Patients With CD3 <sup>+</sup> (Natural Killer) Lymphoproliferative Disease of Granular Lymphocytes. <i>Blood</i> , 1997, 90, 1977-1981.	1.4	55
220	Spontaneous resolution of p58/EB6 antigen restricted NK $\alpha$ C $\beta$ type lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. <i>British Journal of Haematology</i> , 1997, 99, 215-221.	2.5	14
221	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. <i>Blood</i> , 1997, 90, 1115-1123.	1.4	3
222	The natural killer-related receptor for HLA-C expressed on T cells from CD3 <sup>+</sup> lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. <i>Blood</i> , 1996, 87, 2369-2375.	1.4	31
223	Interleukin-15 promotes the growth of leukemic cells of patients with B- cell chronic lymphoproliferative disorders. <i>Blood</i> , 1996, 87, 3327-3335.	1.4	81
224	Skewing of the T-cell receptor repertoire in the lung of patients with HIV-1 infection. <i>Aids</i> , 1996, 10, 729-738.	2.2	21
225	Predictor of the Rate of CD4 Lymphocyte Loss in HIV-1-Seropositive Asymptomatic Hemophiliacs by in Vitro Immunoglobulin Synthesis. <i>Clinical Immunology and Immunopathology</i> , 1996, 81, 224-228.	2.0	1
226	IL $\alpha$ 12 is involved in the activation of CD3 + granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. <i>British Journal of Haematology</i> , 1996, 92, 308-314.	2.5	9
227	HIV and pulmonary immune responses. <i>Trends in Immunology</i> , 1996, 17, 359-364.	7.5	34
228	Lysis of pulmonary fibroblasts by lymphokine (IL $\alpha$ 2) $\alpha$ activated killer cells $\alpha$ a mechanism affecting the human lung microenvironment?. <i>Clinical and Experimental Immunology</i> , 1996, 105, 383-388.	2.6	6
229	Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 153, 1359-1367.	5.6	63
230	Detection of Epstein-Barr Virus by PCR Analyses in Lymphoproliferative Disease of Granular Lymphocytes. <i>Leukemia and Lymphoma</i> , 1996, 23, 371-374.	1.3	16
231	T lymphocytes with $\beta$ $\gamma$ T-cell receptors in patients with AIDS and Pneumocystis carinii pneumonia. <i>Aids</i> , 1995, 9, 203-204.	2.2	7
232	Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. <i>British Journal of Cancer</i> , 1995, 71, 240-245.	6.4	17
233	Childhood onset cyclic neutropenia: G $\alpha$ CSF therapy restores neutrophil count but does not influence superoxide anion and cytokine release by neutrophils. <i>British Journal of Haematology</i> , 1995, 89, 277-281.	2.5	6
234	CD8 <sup>+</sup> T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. <i>Blood</i> , 1995, 85, 2308-2314.	1.4	67



#	ARTICLE	IF	CITATIONS
235	Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 1994, 84, 4249-4256.	1.4	50
236	Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. <i>Cancer</i> , 1994, 74, 2562-2569.	4.1	6
237	CD4 <sup>+</sup> T Cell Receptor Subsets in the Lung of Patients with HIV-1 Infection. <i>Cellular Immunology</i> , 1994, 153, 194-205.	3.0	27
238	Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. <i>British Journal of Cancer</i> , 1994, 69, 1046-1051.	6.4	12
239	In vitro immunoglobulin synthesis as a CD4+ lymphocyte depletion predictor in HIV-1-infected asymptomatic haemophiliacs. <i>Aids</i> , 1994, 8, 1728-1729.	2.2	0
240	CD8 alveolitis in sarcoidosis: Incidence, phenotypic characteristics, and clinical features. <i>American Journal of Medicine</i> , 1993, 95, 466-472.	1.5	46
241	HIV-1 and the Lung: Infectivity, Pathogenic Mechanisms, and Cellular Immune Responses Taking Place in the Lower Respiratory Tract. <i>The American Review of Respiratory Disease</i> , 1993, 147, 1038-1049.	2.9	88
242	Alveolar Macrophages in HIV-1 Infection Express Accessory Molecules, Activation Markers, and Release Increased Biological Response Modifiers. <i>Chest</i> , 1993, 103, 108S-111S.	0.8	10
243	Cellular Immunity in Sarcoidosis and Hypersensitivity Pneumonitis. <i>Chest</i> , 1993, 103, 139S-143S.	0.8	6
244	Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. <i>Blood</i> , 1993, 81, 2723-2727.	1.4	45
245	Persistent polyclonal lymphocytosis in human immunodeficiency virus-1- infected patients. <i>Blood</i> , 1993, 81, 3015-3021.	1.4	6
246	Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 1993, 81, 2381-2385.	1.4	55
247	Alveolar macrophages in HIV-1 infection express accessory molecules, activation markers, and release increased biological response modifiers. <i>Chest</i> , 1993, 103, 108S-111.	0.8	0
248	Cellular immunity in sarcoidosis and hypersensitivity pneumonitis. <i>Recent advances</i> . <i>Chest</i> , 1993, 103, 139S-143.	0.8	0
249	Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. <i>Blood</i> , 1993, 81, 752-758.	1.4	0
250	Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 1993, 81, 2363-2368.	1.4	0
251	Spontaneous Production of Interleukin-6 by Alveolar Macrophages from Human Immunodeficiency Virus Type 1-Infected Patients. <i>Journal of Infectious Diseases</i> , 1992, 166, 731-737.	4.0	63
252	Inhibition of CTL-line lysis after gangliosides treatment. <i>Pharmacological Research</i> , 1992, 26, 190-191.	7.1	0

#	ARTICLE	IF	CITATIONS
253	Role of tumor necrosis factor-alpha and its specific 55-Kd and 75-Kd receptors in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 1992, 80, 2030-2037.	1.4	18
254	Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection. <i>Journal of Clinical Immunology</i> , 1992, 12, 371-380.	3.8	9
255	Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. <i>Cellular Immunology</i> , 1992, 141, 253-259.	3.0	12
256	Phenotypic and functional characterization of cytotoxic cells derived from endomyocardial biopsies in human cardiac allografts. <i>Cellular Immunology</i> , 1992, 141, 332-341.	3.0	9
257	The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 133-142.	1.0	17
258	Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2. <i>Cancer</i> , 1992, 69, 2525-2531.	4.1	6
259	Clonally expanded CD3+, CD4 <sup>+</sup> , CD8 <sup>+</sup> cells bearing the or the T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. <i>Clinical Immunology and Immunopathology</i> , 1991, 60, 371-383.	2.0	10
260	Hepatitis B virus binds to peripheral blood mononuclear cells via the pre S1 protein. <i>Journal of Hepatology</i> , 1991, 12, 203-206.	3.7	35
261	B-ly-7, a monoclonal antibody labeling of activated lung lymphocytes [letter]. <i>Blood</i> , 1991, 77, 1855-1856.	1.4	3
262	Prognostic Significance of the Evaluation of Bronchoalveolar Lavage Cell Populations in Patients with HIV-1 Infection and Pulmonary Involvement. <i>Chest</i> , 1991, 100, 1601-1606.	0.8	41
263	Shedding of the soluble form of the CD8 complex by CD8 +/HLA-DR + cells in HIV-1-infected patients. <i>Aids</i> , 1991, 5, 813-820.	2.2	15
264	Alveolar Macrophages from Patients with AIDS and AIDS-related Complex Constitutively Synthesize and Release Tumor Necrosis Factor Alpha. <i>The American Review of Respiratory Disease</i> , 1991, 144, 195-201.	2.9	51
265	Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. <i>Cancer</i> , 1990, 65, 341-348.	4.1	161
266	Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. <i>Blood</i> , 1990, 75, 1525-1530.	1.4	35
267	Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 1990, 76, 2080-2085.	1.4	34
268	Cytotoxic Events Taking Place in the Lung of Patients with HIV-1 Infection: Evidence of an Intrinsic Defect of the Major Histocompatibility Complex-unrestricted Killing Partially Restored by the Incubation with rIL-2. <i>The American Review of Respiratory Disease</i> , 1990, 142, 516-522.	2.9	22
269	Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. <i>Leukemia Research</i> , 1989, 13, 315-322.	0.8	6
270	Hairy cell sensitivity to the lysis in vitro. <i>Cancer Immunology, Immunotherapy</i> , 1989, 30, 254-256.	4.2	2

#	ARTICLE	IF	CITATIONS
271	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. <i>Cancer</i> , 1989, 64, 667-672.	4.1	16
272	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. <i>Cancer</i> , 1989, 64, 2019-2023.	4.1	15
273	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. <i>Journal of Clinical Immunology</i> , 1989, 9, 401-408.	3.8	8
274	Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 1577-1581.	0.7	5
275	Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. <i>Clinical Immunology and Immunopathology</i> , 1989, 50, 146-153.	2.0	27
276	Pulmonary alveolar macrophages from patients with active sarcoidosis express type IV collagenolytic proteinase. An enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity.. <i>Journal of Clinical Investigation</i> , 1989, 84, 605-612.	8.2	29
277	Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. <i>British Journal of Cancer</i> , 1988, 58, 368-372.	6.4	42
278	Cytotoxic Lymphocytes in the Lungs of Patients with Hypersensitivity Pneumonitis.. <i>Annals of the New York Academy of Sciences</i> , 1988, 532, 447-450.	3.8	5
279	Longitudinal study of alveolitis in hypersensitivity pneumonitis patients: An immunologic evaluation. <i>Journal of Allergy and Clinical Immunology</i> , 1988, 82, 577-585.	2.9	54
280	Different Types of Cytotoxic Lymphocytes Recovered from the Lungs of Patients with Hypersensitivity Pneumonitis. <i>The American Review of Respiratory Disease</i> , 1988, 137, 70-74.	2.9	58
281	Phenotypical and Functional Analysis of Bronchoalveolar Lavage Lymphocytes in Patients with HIV Infection. <i>The American Review of Respiratory Disease</i> , 1988, 138, 1609-1615.	2.9	71
282	HTLV-I ANTIBODIES AND LYMPHOPROLIFERATIVE DISEASE OF GRANULAR LYMPHOCYTES. <i>Lancet</i> , The, 1987, 330, 1527.	13.7	20
283	High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. <i>Blood</i> , 1987, 70, 396-400.	1.4	109
284	Pulmonary alveolar macrophages in patients with sarcoidosis and hypersensitivity pneumonitis: Characterization by monoclonal antibodies. <i>Journal of Clinical Immunology</i> , 1987, 7, 64-70.	3.8	36
285	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. <i>Cancer</i> , 1987, 60, 2412-2418.	4.1	25
286	The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. <i>Cancer</i> , 1987, 60, 2971-2978.	4.1	179
287	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: Evaluation of cytotoxic events. <i>Leukemia Research</i> , 1987, 11, 843-847.	0.8	13
288	Rearrangement for the T-cell receptor gene and co-expression of immature T-cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1987, 65, 17-22.	2.5	8

#	ARTICLE	IF	CITATIONS
289	Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. <i>Blood</i> , 1987, 70, 1530-1535.	1.4	95
290	Activated T Cells with Immunoregulatory Functions at Different Sites of Involvement in Sarcoidosis.. <i>Annals of the New York Academy of Sciences</i> , 1986, 465, 56-73.	3.8	45
291	Alpha-interferon activates the natural killer system in patients with hairy cell leukemia. <i>Blood</i> , 1986, 68, 293-296.	1.4	3
292	Phenotypical and functional analysis of natural killer cells in sarcoidosis. <i>Clinical Immunology and Immunopathology</i> , 1985, 37, 262-275.	2.0	19
293	Bortezomib, Cyclophosphamide, Dexamethasone Versus Lenalidomide, Cyclophosphamide, Dexamethasone in Multiple Myeloma Patients at First Relapse. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0